MBBS (Hons), General and Acute Care Medicine Advanced Physician Trainee, The Alfred Hospital, Melbourne, Vic; Adjunct Lecturer, Central Clinical School, Monash University, Melbourne, Vic.
Aust J Gen Pract. 2023 Jan-Feb;52(1-2):52-57. doi: 10.31128/AJGP-03-22-6365.
Chronic kidney disease mineral and bone disorder (CKD-MBD) is an important cause of morbidity, cardiovascular risk and mortality among patients with chronic kidney disease (CKD). The condition begins to manifest in stage 3a CKD. General practitioners play a crucial part in screening, monitoring and early management of this important problem, which is primarily managed in the community.
The aim of this article is to summarise the key evidence-based principles of the pathogenesis, assessment and management of CKD-MBD.
CKD-MBD includes a spectrum of disease involving biochemical changes, bone abnormalities and vascular and soft tissue calcification. Management is centred on monitoring and controlling biochemical parameters with a variety of strategies to improve bone health and cardiovascular risk. The range of evidence-based treatment options is reviewed in this article.
慢性肾脏病矿物质和骨异常（CKD-MBD）是慢性肾脏病（CKD）患者发病率、心血管风险和死亡率的重要原因。这种情况始于 CKD 第 3a 期。全科医生在筛查、监测和早期管理这一重要问题方面发挥着至关重要的作用，该问题主要在社区中进行管理。
本文旨在总结 CKD-MBD 的发病机制、评估和管理的关键循证原则。
CKD-MBD 包括一系列涉及生化变化、骨骼异常以及血管和软组织钙化的疾病。管理以监测和控制生化参数为中心，采用多种策略来改善骨骼健康和心血管风险。本文回顾了一系列循证治疗选择。
